{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:21:10Z","timestamp":1792614070234,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01AI069911"],"award-info":[{"award-number":["U01AI069911"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23 AI136579"],"award-info":[{"award-number":["K23 AI136579"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K24 AI141036"],"award-info":[{"award-number":["K24 AI141036"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54 CA190153"],"award-info":[{"award-number":["U54 CA190153"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Kaposi\u2019s sarcoma (KS) is one of the most common HIV-associated malignancies in sub-Saharan Africa. Worldwide, the availability of antiretroviral therapy (ART) has improved KS survival. In resource-rich settings, survival has also benefited from chemotherapy, which is widely available. Little is known, however, about the epidemiology of chemotherapy use for HIV-associated KS in resource-limited regions such as sub-Saharan Africa.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We identified all patients newly diagnosed with HIV-related KS from 2009 to 2012 in the 26-clinic AMPATH network, a large community-based care network in Kenya. We ascertained disease severity at diagnosis, frequency of initiation of chemotherapy, and distribution of chemotherapeutic regimens used. Indications for chemotherapy included AIDS Clinical Trial Group T1 stage and\/or \u201csevere\u201d disease defined by WHO KS treatment guidelines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 674 patients diagnosed with KS, charts were available for 588; 61% were men, median age was 35\u2009years, and median CD4 at KS diagnosis was 185 cells\/\u03bcl. At time of diagnosis, 58% had at least one chemotherapy indication, and 22% had more than one indication. For patients with a chemotherapy indication, cumulative incidence of chemotherapy initiation (with death as a competing event) was 37% by 1 month and 56% by 1 year. Median time from diagnosis to chemotherapy initiation was 25\u2009days (IQR 1\u201350\u2009days). In multivariable regression, patients with <jats:underline>&gt;<\/jats:underline>\u20093 chemotherapy indications at time of diagnosis had a 2.30 (95% CI 1.46\u20133.60) increased risk of rapid chemotherapy initiation (within 30\u2009days of diagnosis) compared to those with only one chemotherapy indication (<jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.001). Initial regimens were bleomycin-vincristine (78%), adriamycin-bleomycin-vincristine (11%), etoposide (7%), and gemcitabine (4%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A substantial fraction of patients with KS in East Africa are diagnosed at advanced disease stage. For patients with chemotherapy indications, nearly half did not receive chemotherapy by one year. Liposomal anthracyclines, often used in resource-rich settings, were not first line. These findings emphasize challenges in East Africa cancer care, and highlight the need for further advocacy for improved access to higher quality chemotherapy in this setting.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-019-6506-3","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T19:03:03Z","timestamp":1580324583000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Real-world use of chemotherapy for Kaposi\u2019s sarcoma in a large community-based HIV primary care system in Kenya"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7751-9466","authenticated-orcid":false,"given":"Esther E.","family":"Freeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naftali","family":"Busakhala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick Chite","family":"Asirwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Wenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Seth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khatiya Chelidze","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aggrey","family":"Semeere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Wools-Kaloustian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Bassett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,29]]},"reference":[{"issue":"1","key":"6506_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/COH.0000000000000329","volume":"12","author":"L Chinula","year":"2017","unstructured":"Chinula L, Moses A, Gopal S. HIV-associated malignancies in sub-Saharan Africa: progress, challenges, and opportunities. Curr Opin HIV AIDS. 2017;12(1):89\u201395.","journal-title":"Curr Opin HIV AIDS"},{"issue":"6","key":"6506_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"6506_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12885-016-2080-0","volume":"16","author":"E Freeman","year":"2016","unstructured":"Freeman E, et al. Pitfalls of practicing cancer epidemiology in resource-limited settings: the case of survival and loss to follow-up after a diagnosis of Kaposi's sarcoma in five countries across sub-Saharan Africa. BMC Cancer. 2016;16:65.","journal-title":"BMC Cancer"},{"key":"6506_CR4","volume-title":"J Corrected and excess mortality among HIV-infected individuals diagnosed with Kaposi\u2019s sarcoma in Sub-Saharan Africa, in 19th Workshop on HIV Observational Databases (IWHOD)","author":"A Semeere","year":"2015","unstructured":"Semeere A, Freeman EE, Wenger M, Busakhala A, Bwana C, Yiannoutsos M, Wools-Kaloustian C, Martin K. J Corrected and excess mortality among HIV-infected individuals diagnosed with Kaposi\u2019s sarcoma in Sub-Saharan Africa, in 19th Workshop on HIV Observational Databases (IWHOD). Italy.: Sicily; 2015."},{"issue":"2","key":"6506_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.5588\/pha.13.0003","volume":"3","author":"E Mwinjiwa","year":"2013","unstructured":"Mwinjiwa E, et al. Burden, characteristics, management and outcomes of HIV-infected patients with Kaposi's sarcoma in Zomba. Malawi Public Health Action. 2013;3(2):180\u20135.","journal-title":"Malawi Public Health Action"},{"issue":"11","key":"6506_CR6","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1002\/ijc.28894","volume":"135","author":"J Bohlius","year":"2014","unstructured":"Bohlius J, et al. Kaposi's sarcoma in HIV-infected patients in South Africa: multicohort study in the antiretroviral therapy era. Int J Cancer. 2014;135(11):2644\u201352.","journal-title":"Int J Cancer"},{"key":"6506_CR7","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1186\/s13104-015-1348-9","volume":"8","author":"PL Chalya","year":"2015","unstructured":"Chalya PL, et al. Kaposi's sarcoma: a 10-year experience with 248 patients at a single tertiary care hospital in Tanzania. BMC Res Notes. 2015;8:440.","journal-title":"BMC Res Notes"},{"key":"6506_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1758-2652-13-23","volume":"13","author":"KM Chu","year":"2010","unstructured":"Chu KM, et al. AIDS-associated Kaposi's sarcoma is linked to advanced disease and high mortality in a primary care HIV programme in South Africa. J Int AIDS Soc. 2010;13:23.","journal-title":"J Int AIDS Soc"},{"key":"6506_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13027-019-0242-9","volume":"14","author":"N Busakhala","year":"2019","unstructured":"Busakhala N, et al. Three year survival among patients with aids-related Kaposi sarcoma treated with chemotherapy and combination antiretroviral therapy at Moi teaching and referral hospital. Kenya Infect Agent Cancer. 2019;14:24.","journal-title":"Kenya Infect Agent Cancer"},{"issue":"5","key":"6506_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1200\/JCO.2013.51.6757","volume":"32","author":"M Bower","year":"2014","unstructured":"Bower M, et al. Prospective stage-stratified approach to AIDS-related Kaposi's sarcoma. J Clin Oncol. 2014;32(5):409\u201314.","journal-title":"J Clin Oncol"},{"key":"6506_CR11","unstructured":"Howlader N, Noone AM., Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds), SEER Cancer Statistics Review, 1975-2016, National Cancer Inst 2019."},{"key":"6506_CR12","volume-title":"W.H.O., Guidelines on the treatment of skin and oral HIV-associated conditions in children and adults","author":"(WHO)","year":"2014","unstructured":"(WHO). W.H.O., Guidelines on the treatment of skin and oral HIV-associated conditions in children and adults. Geneva: WHO; 2014."},{"key":"6506_CR13","volume-title":"NCCN harmonized guidelines for Sub-Saharan Africa: Kaposi sarcoma","author":"NCCN","year":"2017","unstructured":"NCCN, NCCN harmonized guidelines for Sub-Saharan Africa: Kaposi sarcoma. 2017."},{"key":"6506_CR14","first-page":"CD003256","volume":"8","author":"OF Gbabe","year":"2014","unstructured":"Gbabe OF, Okwundu CI, Dedicoat M, Freeman EE. Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults. Cochrane Database Syst Rev. 2014;8:CD003256.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"6506_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/QAI.0b013e318251aedd","volume":"60","author":"A Mosam","year":"2012","unstructured":"Mosam A, et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. J Acquir Immune Defic Syndr. 2012;60(2):150\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"6506_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/cid\/ciy044","volume":"67","author":"MC Hosseinipour","year":"2018","unstructured":"Hosseinipour MC, et al. As-needed Vs immediate Etoposide chemotherapy in combination with antiretroviral therapy for mild-to-moderate AIDS-associated Kaposi sarcoma in resource-limited settings: A5264\/AMC-067 randomized clinical trial. Clin Infect Dis. 2018;67(2):251\u201360.","journal-title":"Clin Infect Dis"},{"key":"6506_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13027-018-0177-6","volume":"13","author":"V Fardhdiani","year":"2018","unstructured":"Fardhdiani V, et al. HIV-associated Kaposi's sarcoma in Maputo, Mozambique: outcomes in a specialized treatment center, 2010-2015. Infect Agent Cancer. 2018;13:5.","journal-title":"Infect Agent Cancer"},{"key":"6506_CR18","doi-asserted-by":"publisher","first-page":"19929","DOI":"10.7448\/IAS.18.1.19929","volume":"18","author":"ME Herce","year":"2015","unstructured":"Herce ME, et al. Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi. J Int AIDS Soc. 2015;18:19929.","journal-title":"J Int AIDS Soc"},{"issue":"9","key":"6506_CR19","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1200\/JCO.1989.7.9.1201","volume":"7","author":"SE Krown","year":"1989","unstructured":"Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group oncology committee. J Clin Oncol. 1989;7(9):1201\u20137.","journal-title":"J Clin Oncol"},{"issue":"7","key":"6506_CR20","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/sj.bjc.6602102","volume":"91","author":"JM Satagopan","year":"2004","unstructured":"Satagopan JM, et al. A note on competing risks in survival data analysis. Br J Cancer. 2004;91(7):1229\u201335.","journal-title":"Br J Cancer"},{"issue":"4","key":"6506_CR21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/aje\/kwh221","volume":"160","author":"S Greenland","year":"2004","unstructured":"Greenland S. Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. Am J Epidemiol. 2004;160(4):301\u20135.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"6506_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/1536867X0900900201","volume":"9","author":"P Cummings","year":"2009","unstructured":"Cummings P. Methods for estimating adjusted risk ratios. Stata J. 2009;9(2):175\u201396.","journal-title":"Stata J"},{"key":"6506_CR23","volume-title":"Guidelines for Antiretroviral Drug Therapy in Kenya","author":"National AIDS\/STI Control Program (NASCOP)","year":"2005","unstructured":"National AIDS\/STI Control Program (NASCOP): Guidelines for Antiretroviral Drug Therapy in Kenya. 2005."},{"key":"6506_CR24","volume-title":"Guidelines for Antiretroviral Therapy in Kenya","author":"National AIDS\/STI Control Program (NASCOP)","year":"2011","unstructured":"National AIDS\/STI Control Program (NASCOP): Guidelines for Antiretroviral Therapy in Kenya. 2011."},{"issue":"1","key":"6506_CR25","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1186\/s12885-017-3771-x","volume":"17","author":"CE Bekolo","year":"2017","unstructured":"Bekolo CE, et al. Assessing the outcomes of HIV-infected persons receiving treatment for Kaposi sarcoma in Conakry-Guinea. BMC Cancer. 2017;17(1):806.","journal-title":"BMC Cancer"},{"issue":"3","key":"6506_CR26","doi-asserted-by":"publisher","first-page":"e91020","DOI":"10.1371\/journal.pone.0091020","volume":"9","author":"AA Mwafongo","year":"2014","unstructured":"Mwafongo AA, et al. Treatment outcomes of AIDS-associated Kaposi's sarcoma under a routine antiretroviral therapy program in Lilongwe, Malawi: bleomycin\/vincristine compared to vincristine monotherapy. PLoS One. 2014;9(3):e91020.","journal-title":"PLoS One"},{"issue":"9","key":"6506_CR27","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1097\/QAD.0b013e3282fc9c03","volume":"22","author":"EB El Amari","year":"2008","unstructured":"El Amari EB, et al. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. AIDS. 2008;22(9):1019\u201328.","journal-title":"AIDS"},{"key":"6506_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.19.11000","volume":"5","author":"DH Low","year":"2019","unstructured":"Low DH, et al. Engagement in HIV care and access to Cancer treatment among patients with HIV-associated malignancies in Uganda. J Glob Oncol. 2019;5:1\u20138.","journal-title":"J Glob Oncol"},{"issue":"4","key":"6506_CR29","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/QAI.0b013e31820c011a","volume":"56","author":"MH Bateganya","year":"2011","unstructured":"Bateganya MH, et al. Predictors of survival after a diagnosis of non-Hodgkin lymphoma in a resource-limited setting: a retrospective study on the impact of HIV infection and its treatment. J Acquir Immune Defic Syndr. 2011;56(4):312\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"6506_CR30","first-page":"1","volume":"4","author":"DS O'Neil","year":"2018","unstructured":"O'Neil DS, et al. Quality of breast Cancer treatment at a rural Cancer Center in Rwanda. J Glob Oncol. 2018;4:1\u201311.","journal-title":"J Glob Oncol"},{"key":"6506_CR31","volume-title":"Lister Hill center auditorium","author":"TS Uldrick","year":"2008","unstructured":"Uldrick TS, Mosam A, Shaike F, Friedland G, Skadden D, Jordaan JP, Aboobaker J, Coovadia HM. Prognosis of patients with AIDS-associated Kaposi's sarcoma receiving antiretroviral therapy +\/\u2212 chemotherapy in Kwazulu-Natal, South Africa: An analysis of 1-yr survival data from NCT00380770, in 11th International Conference on Malignacies in AIDS and Other Acquired Immunodeficiencies. In: Lister Hill center auditorium. NIH, Bethesda, Maryland: National Library of Medicine; 2008."},{"issue":"6","key":"6506_CR32","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/ijd.14305","volume":"58","author":"Christa Slaught","year":"2018","unstructured":"Slaught C, Williams V, Grover S, et al. A retrospective review of patients with Kaposi's sarcoma in Botswana. Int J Dermatol. 2019;58(6):707\u201312.","journal-title":"International Journal of Dermatology"},{"issue":"1","key":"6506_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/01.qai.0000232260.95288.93","volume":"43","author":"MV Brock","year":"2006","unstructured":"Brock MV, et al. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr. 2006;43(1):47\u201355.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"6506_CR34","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1136\/thx.2005.052373","volume":"61","author":"J Cadranel","year":"2006","unstructured":"Cadranel J, et al. Lung cancer in HIV infected patients: facts, questions and challenges. Thorax. 2006;61(11):1000\u20138.","journal-title":"Thorax"},{"issue":"6","key":"6506_CR35","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1634\/theoncologist.2015-0387","volume":"21","author":"CA Brown","year":"2016","unstructured":"Brown CA, et al. Predictors of timely access of oncology services and advanced-stage Cancer in an HIV-endemic setting. Oncologist. 2016;21(6):731\u20138.","journal-title":"Oncologist"},{"issue":"5","key":"6506_CR36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/QAI.0000000000000360","volume":"67","author":"E Rohner","year":"2014","unstructured":"Rohner E, et al. Incidence rate of Kaposi sarcoma in HIV-infected patients on antiretroviral therapy in southern Africa: a prospective multicohort study. J Acquir Immune Defic Syndr. 2014;67(5):547\u201354.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"13","key":"6506_CR37","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1056\/NEJMc070508","volume":"357","author":"T Maurer","year":"2007","unstructured":"Maurer T, Ponte M, Leslie K. HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. N Engl J Med. 2007;357(13):1352\u20133.","journal-title":"N Engl J Med"},{"key":"6506_CR38","unstructured":"ClinicalTrials.gov. Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS. ClinicalTrials.gov Identifier: NCT01435018. [cited November 2018]."},{"issue":"11","key":"6506_CR39","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJMra1615896","volume":"378","author":"R Yarchoan","year":"2018","unstructured":"Yarchoan R, Uldrick TS. HIV-associated cancers and related diseases. N Engl J Med. 2018;378(11):1029\u201341.","journal-title":"N Engl J Med"},{"key":"6506_CR40","volume-title":"As Cancer Tears Through Africa, Drug Makers Draw Up a Battle Plan, in The New York Times","author":"D McNeil Jr","year":"2017","unstructured":"McNeil D Jr. As Cancer Tears Through Africa, Drug Makers Draw Up a Battle Plan, in The New York Times; 2017."},{"issue":"8","key":"6506_CR41","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1080\/13691058.2013.791057","volume":"15","author":"A Conroy","year":"2013","unstructured":"Conroy A, Yeatman S, Dovel K. The social construction of AIDS during a time of evolving access to antiretroviral therapy in rural Malawi. Cult Health Sex. 2013;15(8):924\u201337.","journal-title":"Cult Health Sex"},{"issue":"14","key":"6506_CR42","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1002\/cncr.26681","volume":"118","author":"AJ Price","year":"2012","unstructured":"Price AJ, et al. Cancer care challenges in developing countries. Cancer. 2012;118(14):3627\u201335.","journal-title":"Cancer"},{"key":"6506_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13027-017-0124-y","volume":"12","author":"V Vanderpuye","year":"2017","unstructured":"Vanderpuye V, et al. An update on the management of breast cancer in Africa. Infect Agent Cancer. 2017;12:13.","journal-title":"Infect Agent Cancer"},{"issue":"4","key":"6506_CR44","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/jan.13476","volume":"74","author":"R Mansell","year":"2018","unstructured":"Mansell R, Purssell E. Treatment abandonment in children with cancer in Sub-Saharan Africa: systematic literature review and meta-analysis. J Adv Nurs. 2018;74(4):800\u20138.","journal-title":"J Adv Nurs"},{"issue":"3","key":"6506_CR45","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1089\/jpm.2017.0257","volume":"21","author":"D Low","year":"2018","unstructured":"Low D, et al. End-of-life palliative care practices and referrals in Uganda. J Palliat Med. 2018;21(3):328\u201334.","journal-title":"J Palliat Med"},{"issue":"6","key":"6506_CR46","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1200\/JGO.2016.007385","volume":"3","author":"D Low","year":"2017","unstructured":"Low D, et al. Chemotherapy use at the end of life in Uganda. J Glob Oncol. 2017;3(6):711\u20139.","journal-title":"J Glob Oncol"},{"key":"6506_CR47","doi-asserted-by":"crossref","unstructured":"Cancer control in Africa: infrastructure, not philanthropy. Lancet Oncol. 2017;18(11):1423.","DOI":"10.1016\/S1470-2045(17)30788-X"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6506-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6506-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6506-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:13:13Z","timestamp":1611792793000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6506-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,29]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6506"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6506-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,29]]},"assertion":[{"value":"4 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Moi Teaching and Referral Hospital Institutional Research and Ethics Committee, Kenya. Secondary data analysis at Massachusetts General Hospital was deemed IRB exempt by the Partners Healthcare IRB. A waiver of consent for the secondary data analysis was approved by the Partners Healthcare IRB due to the completely anonymized nature of the dataset, which did not include any patient identifiers.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No individually identifiable data \u2013 not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}